Found 5 op-ophthalmology trials
A listing of op-ophthalmology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Safety and Efficacy of IONIS-FB-Lrx in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
The purpose of this study is to assess the Safety and Efficacy of IONIS-FB-Lrx patients with Geographic Atrophy secondary to Age Related Macular Degeneration
A Multiple-Site Phase 1/2 Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients with Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
Achromatopsia is an inherited retinal disorder characterized by markedly reduced visual acuity, nystagmus, photoaversion (intolerance to bright light), a small central scotoma, eccentric viewing, and complete or severe loss of color discrimination. The genetic mutations of the disease can be established in the majority of individuals. Approximately 50% are caused …
PPS Study- Screening and Classification of Pentosan-Associated Maculopathy in Patients with Interstitial Cystitis
The primary objective of this study is to determine the prevalence of retinal changes in patients using pentosan polysulfate sodium (PPS) for treatment of interstitial cystitis and further characterize this condition using multimodal imaging. Additionally, this study aims to identify additional clinical findings associated with PPS maculopathy and to gain …
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Stage 2 and 3 Neurotrophic Keratitis Subjects
The purpose of this study is to compare the safety and effectiveness of the study product, CSB-001 ophthalmic solution 0.1% to placebo when treating stage 2 and 3 Neurotrophic Keratitis.
DEFENDO- Study to evaluate safety and efficacy of ophthalmic solution (Oxervate) in patients with Stage 1 Neurotrophic Keratitis (NK)
This clinical study will be a multi-center, open label, prospective study of 8 weeks of treatment with 24 weeks of follow-up to evaluate the safety and efficacy of OXERVATE 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution administered as one drop in the affected eye(s), 6 times per day at 2-hour intervals, …
Please choose between Voice or SMS based delivery of verification code
or